GC Biopharma, a South Korean biopharmaceutical company, announced on Feb. 10th that it presented development updates on its ...
Denali announces encouraging additional longer-term data from the phase I/II Hunter Syndrome study of its investigational therapy, tividenofusp alfa.
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...
Zacks.com on MSN8d
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug StudyUltragenyx Pharmaceutical RARE reported new findings from an ongoing, pivotal study of its investigational candidate, UX111 (ABO-102) AAV gene therapy, for Sanfilippo syndrome type A (MPS IIIA). Per ...
Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant ...
California, USA-based rare disease company Ultragenyx Pharmaceutical yesterday released new data demonstrating treatment with UX111 (ABO-102) AAV gene therapy led to a statistically-significant ...
NOVATO, Calif. - Ultragenyx Pharmaceutical Inc. (NASDAQ: NASDAQ:RARE), a $4.08 billion market cap biotechnology company with 27% revenue growth in the past year, today unveiled new data indicating ...
Joseph Arboleda-Velasquez of Harvard Medical School praised the results. “Ye’s group has now provided compelling evidence showing increased binding affinity of ApoE3 Christchurch for tau and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback